Alkermes Announces Launch of 8th Annual Alkermes Pathways Research Awards® Program

Core Points - Alkermes plc is launching its 8th annual Alkermes Pathways Research Awards program, which will accept applications from September 15, 2025, to December 15, 2025, offering individual grants of up to $100,000 per project [1][2][3] - The program aims to support early-career researchers focusing on schizophrenia, bipolar I disorder, and newly included areas of sleep and circadian disturbances associated with these conditions [2][3] - Since its inception in 2018, the program has provided approximately $2.7 million in funding to 27 researchers across the United States [4] Company Overview - Alkermes plc is a mid-cap growth and value equity global biopharmaceutical company focused on developing innovative medicines in neuroscience [5] - The company has a portfolio of proprietary commercial products for treating alcohol dependence, opioid dependence, schizophrenia, and bipolar I disorder, along with a pipeline for neurological disorders [5]